NCT05630209 - Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions

Brain Tumor

Interventions

DEVICE

Exablate

Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors

DRUG

Doxorubicin

Doxorubicin infusion

Trial Locations (3)

20010

RECRUITING

Children's National Medical Center, Washington D.C.

33155

RECRUITING

Nicklaus Children's Hospital, Miami

76104

RECRUITING

Cook Children's Health Care System, Fort Worth